Analyze self-interaction to predict viscosity and aggregation propensity at higher concentrations

Biologic therapeutics developed during early discovery workflows must retain their functionality once it is time to manufacture and deliver them to customers. Researchers in these early phases of development have many parameters they profile to better predict the long-term behavior of their candidates, including the self-interaction parameter kD. It is a useful indicator of whether aggregation or viscosity issues will manifest upon scale-up and packaging for clinical use.

The DLS capabilities of Prometheus Panta enable researchers to accurately measure the kD of their formulations and find the conditions that reduce the chances of aggregation at high concentrations. Read this technical note to better understand how formulation and concentration has an impact on the behavior of biologic candidates.

Previous Article
Understanding unfolding and refolding of the antibody fragment (Fab). I. In-vitro study
Understanding unfolding and refolding of the antibody fragment (Fab). I. In-vitro study

Up next
DLS easily explained: What it tells you about your protein
DLS easily explained: What it tells you about your protein

Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and se...

Want to see more
biologics content?

Explore resources